Article Text

Download PDFPDF

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France
  1. T Lequerré1,
  2. P Quartier2,
  3. D Rosellini2,
  4. F Alaoui3,
  5. M De Bandt4,
  6. O Mejjad1,
  7. I Kone-Paut5,
  8. M Michel6,
  9. E Dernis7,
  10. M Khellaf6,
  11. N Limal8,
  12. C Job-Deslandre9,
  13. B Fautrel10,
  14. X Le Loët1,
  15. J Sibilia3,
  16. on behalf of the Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP) and the Club Rhumatismes et Inflammation (CRI)
  1. 1
    Rheumatology Department, Rouen University Hospital & Inserm 905, Rouen, France
  2. 2
    Paediatric Immuno-Haematology and Rheumatology Department, Necker-Enfants Malades Hospital, Paris, France
  3. 3
    Rheumatology Department, CHU Strasbourg, Strasbourg, France
  4. 4
    Rheumatology Department, Hôpital Robert Ballanger, Aulnay sous Bois, France
  5. 5
    Paediatric Department, Bicêtre Hospital, Le Kremlin-Bicêtre, France
  6. 6
    Department of Internal Medicine, Hôpital Henri Mondor, Créteil, France
  7. 7
    Rheumatology Department, Hôpital Le Mans, Le Mans, France
  8. 8
    Department of Internal Medicine, Hôpital Pitié Salpétrière, France
  9. 9
    Rheumatology A Department, Cochin Hospital, Paris, France
  10. 10
    Rheumatology Department, Hôpital Pitié-Salpétrière, Paris, France
  1. T Lequerré, Rheumatology Department, Rouen University Hospital & Inserm 905, 76031 Rouen, France; thierry.lequerre{at}univ-rouen.fr. Pierre Quartier, Unité d’Immunologie-Hématologie et Rhumatologie pédiatrique, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75015 Paris, France; quartier{at}necker.fr

Abstract

Background: Anakinra treatment has been reported to be effective in some patients with systemic-onset juvenile idiopathic arthritis (SoJIA) or adult-onset Still disease (AoSD).

Objectives: To assess the efficacy and the safety of anakinra treatment in SoJIA and AoSD.

Methods: SoJIA and AoSD patients were treated with anakinra (1–2 mg/kg/day in children, 100 mg/day in adults); we analysed its effect on fever, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels, numbers of swollen and tender joints, the assessment of disease activity (by physician and parent/patient) and pain (by parent/patient), and American College of Rheumatology (ACR) pediatric core set criteria for JIA activity.

Results: A total of 35 patients were included, 20 with SoJIA and 15 with AoSD. Their mean age (range) at the onset of treatment was 12.4 (3–23) and 38.1 (22–62) years, respectively; disease duration was 7.0 (1–16) and 7.8 (2–27) years, respectively. Active arthritis was present in all cases but one. Of the 20 SoJIA patients, 5 achieved ACR 50% improvement in symptoms (ACR50) response criteria at 6 months. Steroid dose had been decreased by 15% to 78% in 10 cases. A total of 11 of the 15 AoSD patients achieved at least a 50% improvement for all disease markers (mean follow-up: 17.5 (11–27) months). Steroids had been stopped in two cases and the dose was decreased by 45% to 95% in 12 patients. Two patients stopped anakinra due to severe skin reaction, and two patients due to infection: one visceral leishmaniasis and one varicella.

Conclusion: Anakinra was effective in most AoSD patients, but less than half SoJIA patients achieved a marked and sustained improvement.

View Full Text

Statistics from Altmetric.com

Footnotes

  • See editorial on p 281

  • TL and PQ contributed equally to this work.

  • Competing interests: None declared.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles